Login / Signup

YES, a novel therapeutic target in hepatocellular carcinoma.

Marjorie LapougeSylvain Meloche
Published in: Molecular & cellular oncology (2022)
Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies the tyrosine kinase YES as a potential therapeutic target in HCC.
Keyphrases